The prostate health index selectively identifies clinically significant prostate cancer

Journal of Urology

Volumn 193, Issue 4, 2015, Pages 1163-1169

  Loeb, Stacy ^a   Sanda, Martin G ^b   Broyles, Dennis L ⁱ   Shin, Sanghyuk S ⁱ   Bangma, Chris H ^c   Wei, John T ^d   Partin, Alan W ^e   Klee, George G ^f   Slawin, Kevin M ^g   Marks, Leonard S ^h   Van Schaik, Ron H N ^c   Chan, Daniel W ^e   Sokoll, Lori J ^e   Cruz, Amabelle B ⁱ   Mizrahi, Isaac A ⁱ   Catalona, William J ^j  

^a NEW YORK UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g Texas Prostate Center   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BECKMAN COULTER INC   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

biological markers; early detection of cancer; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; (-2)PRO-PROSTATE-SPECIFIC ANTIGEN, HUMAN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GENITAL SYSTEM DISEASE ASSESSMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; HEALTH STATUS INDICATOR; MIDDLE AGED; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS;

EID: 84926421143     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.10.121     Document Type: Article

References (24)

1. V.A. Moyer Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120
2. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027
3. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125
4. A. Christensson, T. Bjork, and O. Nilsson Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer J Urol 150 1993 100
5. M. Lazzeri, A. Haese, and A. de la Taille Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study Eur Urol 63 2013 986
6. M.A. Khan, A.W. Partin, and H.G. Rittenhouse Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml J Urol 170 2003 723
7. W.J. Catalona, A.W. Partin, and M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
8. S. Isharwal, D.V. Makarov, and L.J. Sokoll ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program Urology 77 2011 763.e1
9. J.J. Tosoian, S. Loeb, and Z. Feng Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer J Urol 188 2012 1131
10. H. Hirama, M. Sugimoto, and K. Ito The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort J Cancer Res Clin Oncol 140 2014 257
11. F.H. Jansen, R.H. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 50 2010 921
12. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359
13. G. Qin, Y.S. Hsu, and X.H. Zhou New confidence intervals for the difference between two sensitivities at a fixed level of specificity Stat Med 25 2006 3487
14. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
15. C.F. Ng, P.K. Chiu, and N.Y. Lam The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL Int Urol Nephrol 46 2014 711
16. K. Ito, M. Miyakubo, and Y. Sekine Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range World J Urol 31 2013 305
17. C. Stephan, S. Vincendeau, and A. Houlgatte Multicenter evaluation of [-2]proprostate-specific antigen and the Prostate Health Index for detecting prostate cancer Clin Chem 59 2013 306
18. X. Filella, and N. Gimenez Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis Clin Chem Lab Med 51 2013 729
19. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection Version 2014. Available at http://www.nccn.org/professionals/physician-gls/pdf/prostate-detection.pdf. Accessed May 26, 2014.
20. M.J. Roobol, D. Nieboer, and A. Houlgatte Reducing unnecessary biopsies for suspicion of prostate cancer: extension and validation of an ERSPC based risk calculator with phi and comparison with the PCPT risk calculator including %free and -2proPSA J Urol 189 suppl. 2013 e843 abstract 2054
21. Roobol M, Salman J and Azevedo N: The Rotterdam prostate cancer risk calculator: improved prediction with more relevant pre-biopsy information, now in the palm of your hand. Presented at EAU Stockholm, April 11-15, 2014, abstract 857.
22. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534
23. M. Ferro, D. Bruzzese, and S. Perdona Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml PLoS One 8 2013 e67687
24. S. Loeb, M.A. Bjurlin, and J. Nicholson Overdiagnosis and overtreatment of prostate cancer Eur Urol 65 2014 1046